Separation Agreement and General ReleaseConsulting Agreement • January 8th, 2020 • Rhythm Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
This separation agreement and general release (“Agreement”) confirms our mutual agreement regarding the terms and conditions of the separation of Dr. Keith Gottesdiener (referred to throughout this Agreement as “you” or “your”) from his employment with Rhythm Pharmaceuticals, Inc., a Delaware corporation (the “Company”). You and the Company agree as follows:
RHYTHM PHARMACEUTICALS, INC. CONSULTING AGREEMENTConsulting Agreement • January 8th, 2020 • Rhythm Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
This CONSULTING AGREEMENT (this “Agreement”) is entered into as of January 6, 2020, by and between Rhythm Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, and Keith Gottesdiener, M.D. (the “Consultant”). This Agreement will be effective on the date (the “Effective Date”) immediately following the Last Day of Employment (as such term is defined in that certain Separation Agreement, dated of even date herewith (the “Separation Agreement”), between the Company and the Consultant) if the Consultant continues to be an employee of the Company through the Last Day of the Transition Period (as such term is defined in the Separation Agreement); provided, however, that if the Consultant does not continue to be an employee of the Company through the Last Day of the Transition Period, then this Agreement shall not become effective, there shall be no Effective Date, the Term of this Agreement shall not commence and this Agreement shall automatically terminate and become null and void
